Growing evidence indicates that inflammation is a contributing factor leading to cancer development. However, pathways involved in this progression are not well understood. To examine whether HIF-1α is a factor linking inflammation and tumorigenesis, we investigated whether the HIF-1 signaling pathway was stimulated by the pro-inflammatory cytokine interleukin-1β (IL-1β) in A549 cells. We find that IL-1β up-regulated HIF-1α protein under normoxia and activated the HIF-1-responsive gene vascular endothelial growth factor (VEGF) via a pathway dependent on nuclear factor κB (NFkB). Interestingly, although this pathway is stimulated by upstream signaling via AKT and mTOR and requires new transcription, IL-1 mediated HIF-1α induction also utilizes a post-transcriptional mechanism that involves antagonism of VHL-dependent HIF-1α degradation, which results in increased HIF-1α protein stability. IL-1 mediated NFkB-dependent cyclooxygenases-2 (COX-2) expression served as a positive effector for HIF-1α induction. Although COX-2 inhibitors attenuated IL-1 mediated HIF-1α induction, prostaglandin E 2 (PGE 2 ), a physiological product of COX-2, induced HIF-1α protein in a dose-dependent manner. Our data, therefore, demonstrate that IL-1β up-regulates functional HIF-1α protein through a classical inflammatory signaling pathway involving NFkB and COX-2, culminating in up-regulation of VEGF, a potent angiogenic factor required for tumor growth and metastasis. Thus, HIF-1 is identified as a pivotal transcription factor linking the inflammatory and oncogenic pathways.
time quantification of VEGF and HIF-1α mRNA was performed by using SYBR Green I dye (Applied Biosystems, Foster City, CA) with the following primer pairs:
Human HIF-1α forward 5′-TCCAGTTACGTTCCTTCGATCA-3′
Human HIF-1α Reverse 5′-TTTGAGGACTTGCGCTTTCA-3′
Human VEGF forward 5′-TCTACCTCCACCATGCCAAGT-3′
Human VEGF reverse 5′-GATGATTCTGCCCTCCTCCTT-3′ SYBR Green I, double-stranded DNA binding dye, was detected by using the laser-based ABI Prism 7700 Sequence Detection System (Applied Biosystems). PCR amplification was performed by using an optical 96-well reaction plate and caps. The final reaction mixture of 25 µL consisted of 200 nM each primer, 1 × SYBR Green PCR Master Mix (Applied Biosystems) containing a reference dye, and cDNA at the following conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, and 60°C for 1 min. The cDNAs were prepared from each RNA sample by using a TaqMan Reverse Transcription Kit (Applied Biosystems).
VEGF ELISA
Cells were treated with the indicated drugs in the presence or absence of IL-1β for 8 h, and immunoreactive VEGF protein in cellular supernatants was measured by using a Quantikine VEGF ELISA kit (R&D systems).
RESULTS

IL-1β induces HIF-1α protein in a time-dependent manner
In a previous study, we found that the proinflammatory cytokine TNF-α induced HIF-1α protein in normoxia (32) . The proinflammatory cytokine IL-1β exerts many biological effects that are shared with TNF-α. (39) . Furthermore, several studies suggest that IL-1β can increase HIF-1 DNA binding and VEGF production, which suggests a link between this cytokine and HIF-1α regulation (30, 40, 41) . For these reasons, we tested whether IL-1β was similarly able to induce HIF-1α protein. The lung epithelial cell line A549 was treated under normoxia with IL-1β for the indicated times and was lysed, and HIF-1α was immunoblotted from nuclear extracts. As shown in Fig. 1 , HIF-1α protein was markedly induced by IL-1β at 4 h, and these induced levels persisted for over 4 h during this treatment.
HIF-1α induction by IL-1β is mediated by NFkB
We next examined whether the IL-1 effect upon HIF-1α induction was dependent upon transcription. Cells were treated with IL-1β in the presence of the transcription inhibitor actinomycin D, and HIF-1α protein levels were detected by Western blot. As shown in Fig. 2A , HIF-1α induction by IL-1β was completely inhibited by pretreatment with actinomycin D. In contrast, transcriptional inhibition did not affect HIF-1α protein induced by hypoxia, which operates solely via a post-transcriptional mechanism (42) . We next examined whether the IL-1 mediated induction of HIF-1α occurred specifically through an NFkB-dependent pathway. Cells were transiently transfected with an NFkB-dependent luciferase reporter construct to monitor NFkB activity in response to IL-1β. As shown in Fig. 2B , IL-1β treatment elicited at least a fivefold induction of NFkB activity. However, treatment of cells with D609, an inhibitor of NFkB, or cotransfection with NFkB super repressor (NFRP) both dramatically reduced NFkB activity. To determine whether activation of NFkB is required for HIF-1α induction, a similar experiment was performed and HIF-1α protein levels were monitored. As shown in Fig. 2C (upper panel), all NFkB inhibitors tested significantly attenuated the ability of IL-1β to upregulate HIF-1α protein levels. To ensure that the action of these inhibitors was specific for the NFkB-mediated pathway of HIF-1α induction, these inhibitors were added to cells treated with the hypoxia mimetic cobalt chloride. As shown in Fig. 2C (lower panel) , NFkB inhibitors were unable to interfere with the CoCl 2 -mediated up-regulation of HIF-1α, thus demonstrating specificity for the IL-1-mediated pathway. As IL-1 induced HIF-1α protein via NFkB-mediated transcription, we determined whether this cytokine modulated HIF-1α protein by increasing its mRNA levels. As shown in Fig. 2D , RT-PCR analysis revealed that HIF-1α mRNA levels remained unchanged in response to either IL-1β, hypoxia, or hypoxia mimetics (Fig. 2D, upper  panel) . Beta actin was used as an internal control ( Fig. 2A, lower panel) .
PI-3 kinase-AKT-mTOR is an upstream signaling pathway for IL-1 mediated NFkB activation and HIF-1α induction
Given that NFkB is required for IL-1 mediated HIF-1α induction, we next sought to dissect the upstream events in this pathway. Because IL-1 activates NFkB through the PI-3 kinase-AKT pathway in many cell types (43) and PI-3 kinase-AKT-mTOR is a signaling pathway leading to induction of HIF-1α in normoxia (44), we assessed whether this pathway was also involved in IL-1 mediated HIF-1α induction. First, we examined whether the PI-3 kinase-AKT pathway was involved in the activation of NFkB by IL-1β. We treated cells with IL-1β in the presence of the specific PI-3 kinase inhibitor LY-294002 and monitored effects of this reagent on phosphorylation of serine 473 of AKT, which represents the activated form of this protein. As shown in Fig. 3A , treatment with IL-1β markedly induced AKT phosphorylation without altering AKT protein levels and LY-294002 completely inhibited this phosphorylation, indicating that IL-1β activates AKT in a PI-3 kinase-dependent manner in this cell line. We next examined whether the inhibitory effect of this reagent on AKT attenuated NFkB activity. Cells were transiently transfected with NFkB-dependent luciferase plasmid and incubated with IL-1β in the presence of LY294002. Rapamycin effects upon NFkB were also tested, as rapamycin is a specific inhibitor of mTOR kinase (45) , which is downstream of PI-3K/AKT. Although basal NFkB activity was not affected by either LY-294002 or rapamycin (data not shown), both LY-294002 and rapamycin attenuated NFkB activity mediated by IL-1β (~60 and 40%, respectively; Fig. 3B ). Because our hypothesis is that activation of the AKT pathway by IL-1β leads to activation of NFkB and subsequent up-regulation of HIF-1α protein, then inhibition of NFkB by these agents should correlate with a reduction in HIF-1α protein level. To test this, cells were treated as in Fig. 3B and HIF-1α protein was immunoblotted from nuclear extracts. As shown in Fig. 3C , HIF-1α protein levels were significantly decreased in the presence of either LY294002 or rapamycin. Therefore, HIF-1α protein levels correlate with NFkB activity and are further dependent on activation of the AKT pathway in response to this cytokine. regulation. One strong candidate gene for NFkB-mediated HIF-1α up-regulation is COX-2. COX-2 is an NFkB-inducible gene that plays important roles in both inflammation and carcinogenesis and is further implicated in modulating VEGF expression (18) , a target gene of HIF-1. We therefore considered the possibility that COX-2 might be involved in the IL-1 mediated NFkB-induced HIF-1α up-regulation. First, to test whether IL-β could induce COX-2 in an NFkB-dependent manner, cells were treated with IL-1β in the presence of NFkB inhibitors D609 or NFkB super repressor plasmid and COX-2 expression was monitored by Western blot. As shown in Fig. 4A , COX-2 protein was induced in response to IL-1β and this induction was significantly inhibited by both NFkB inhibitors, which is well correlated with inhibition of IL-1-induced NFkB activation by the reagents in Fig. 2B . Next, to examine whether NFkB-induced COX-2 was involved in HIF-1α induction, cells were treated with IL-1β in the presence of COX-2 inhibitors and HIF-1α protein was examined. As shown in Fig. 4B (upper panel), HIF-1α induction by IL-1β was inhibited by both the specific COX-2 inhibitor NS-398 in a dosedependent manner and the non-selective COX-2 inhibitor indomethacin. Although COX-1 is not inducible by proinflammatory cytokines (46), we examined whether COX-1 contributes to IL-1 mediated HIF-1α induction. Thus, the same experiment was performed in the presence of the specific COX-1 inhibitor SC-560. As shown in Fig. 4B (lower panel), SC-560 was unable to interfere with the ability of IL-1β to induce HIF-1α protein, thus confirming the specificity for COX-2.
To further confirm an involvement of COX-2 in IL-1-mediated HIF-1α induction, the inhibitory effect of the specific COX-2 inhibitor NS-398 was investigated in the colon epithelial cell line CaCo-2. Because COX-2 plays an important role in the initiation and progression of colon cancer (20, 47) , we examined whether COX-2 is involved in the regulation of HIF-1α protein levels in this cell line. As shown in Fig. 4C (upper panel), COX-2 was strongly induced in response to IL-1β and was inhibited by the NFkB inhibitors PDTC or BAY 11-7082. Similar to A549 cells, inhibition of COX-2 (here mediated by NS-398) correlated with a dose-dependent attenuation of IL-1 induced HIF-1α protein (Fig. 4C , lower panel).
To provide further support for the notion that COX-2 is involved in the regulation of HIF-1α protein levels, we investigated whether prostanoids, biologically active products of COX-2 (21), also result in HIF-1α induction. We treated A549 cells with PGE 2 and assessed HIF-1α protein levels from nuclear extracts. As shown in Fig. 4D , PGE 2 induced HIF-1α protein in a dosedependent manner. Interestingly, this up-regulation was extremely rapid, with significant HIF-1α protein accumulation evident within 1 h of treatment.
Induction of HIF-1α by IL-1β is dependent on VHL function
Although transcriptional mechanisms play a role in the IL-1-mediated up-regulation of HIF-1α, our data indicated that IL-1 induced HIF-1α via a post-transcriptional mechanism. Because biological stimuli, such as TNF-α, promote HIF-1α protein accumulation in normoxia by posttranscriptional mechanisms involving increased protein stability (32, 48) , we examined whether IL-1β could also stabilize HIF-1α protein. Cells were incubated in the presence or absence of IL-1β for 4 h and were further incubated for the indicated times in the presence of cycloheximide. To make the initial loading amount of HIF-1α protein similar, approximately threefold more nuclear protein of the control sample was loaded as evidenced by the stronger ARNT signal in the lanes not treated with IL-1β. As shown in Fig. 5A , although endogenous HIF-1α protein was extremely labile, with less than a 4-min half-life, IL-1β treatment stabilized HIF-1α protein and extended its half-life approximately threefold. These data indicated that IL-1β induced HIF-1α protein by increasing its protein stability.
One of the main regulators of HIF-1α protein stability is the ubiquitin protein ligase VHL (2); therefore, we investigated the possible involvement of VHL in IL-1 mediated HIF-1α stabilization. IL-1β was treated in a matched pair of renal carcinoma cells lines either lacking VHL function (UMRC2) or with VHL replaced (UMRC2/VHL). In response to IL-1β, no further accumulation of HIF-1α was seen in the VHL-deficient UMRC2 line, whereas HIF-1α protein was further induced in VHL-restored UMRC2 cells (Fig. 5B, upper panel) . To confirm this result in our experimental model, A549 cells were transfected with HA-tagged wild-type HIF-1α plasmid (VHL-sensitive) or HA-tagged proline mutated HIF-1α (VHL-resistant; 42) and treated with IL-1β, and transfected HIF-1α protein was detected with an HA-specific antibody. Consistent with the results in the UMRC2 pair, wild-type HIF-1α, but not proline mutated HIF-1α, was induced in response to IL-1β (Fig. 5B, lower panel) , thereby demonstrating that initial sensitivity to VHL is a requirement for subsequent IL-1-mediated HIF-1α induction.
IL-1 mediated HIF-1α up-regulation stimulates VEGF production
Our results indicated that inflammatory stimuli involving NFkB and COX-2 could up-regulate HIF-1α protein. Because vascular endothelial growth factor (VEGF), a potent angiogenic factor, is one of the HIF-1 target genes through which HIF-1 plays a critical role in tumor progression (49), we examined whether IL-1 up-regulated HIF-1 induced VEGF levels. We treated cells with IL-1β and analyzed VEGF mRNA levels either in the absence or presence of the specific HIF-1 inhibitor NSC-609699 (50). The HIF-1 inhibitor was used to determine background levels of VEGF and to assess the HIF-1 dependency of IL-1 mediated VEGF induction. As shown in Fig.  6A , IL-1β induced VEGF mRNA approximately threefold and this effect was completely inhibited by the HIF-1 specific inhibitor. To confirm this result, we treated cells with IL-1β in the presence or absence of the HIF-1 inhibitor and examined accumulation of immunoreactive VEGF in the cell culture supernatants. Consistent with the data in Fig. 6A is that, although IL-1β enhanced VEGF secretion, the HIF-1 inhibitor completely prevented this increase, with VEGF levels returning to those of the control (Fig. 6B) . Because COX-2 also appears to be a mediator of HIF-1α induction, we examined whether COX-2 is implicated inVEGF up-regulation by IL-1β. Cells were treated with IL-1β in the presence of the COX-2 inhibitors indomethacin or NS-398, and immunoreactive VEGF in the supernatants was measured. As shown in Fig. 6C , COX-2 inhibitors significantly inhibited the IL-1β stimulated accumulation of VEGF by more than 50%, consistent with our data demonstrating inhibition of the IL-1β stimulatory effect of HIF -1α by these same agents (Fig. 4B ).
DISCUSSION
In this study, HIF-1 is identified as a molecular link between the inflammatory and oncogenic pathways. We demonstrate that a major inflammatory cytokine, IL-1β, up-regulates HIF-1α protein via an inflammatory signaling pathway involving NFkB and COX-2, culminating in increased VEGF secretion. Our data demonstrate that IL-1 mediated HIF-1α induction is dependent upon NFkB transcriptional activity and that this activity is well-correlated with HIF-1α protein levels. We have previously reported NFkB-mediated HIF-1α up-regulation by TNF-α and microtubule-depolymerizing agents (32, 51) , thereby illustrating the central role of NFkB in non-hypoxic HIF-1α regulation. However, although the NFkB pathway is necessary for HIF-1 induction, each stimulus activates NFkB by a distinct mechanism (52, 53) . Because NFκB is an ubiquitous transcription factor known to be activated by a wide variety of stimuli (54, 55) , our data suggest that numerous signaling pathways converge upon NFkB to participate in HIF-1α regulation and that HIF-1 activation may occur in response to diverse cellular stimuli in addition to hypoxia.
Although some stimuli can promote HIF-1α protein up-regulation as a result of increased translation (56) , our data suggest that IL-1 up-regulates HIF-1α by stabilizing the protein. First, we show that IL-1 mediated HIF-1α up-regulation occurs at the post-transcriptional level. Second, we demonstrate that disappearance of HIF-1α protein following inhibition of protein synthesis in IL-1β treated cells is significantly delayed compared with untreated cells. Third, we find that IL-1 mediated HIF-1α up-regulation is dependent upon the presence of functional VHL. Although functional VHL is required to observe IL-1 mediated HIF-1α inducibility, the steadystate levels of HIF-1α induced by IL-1β are less than those induced by hypoxia, suggesting that IL-1 mediated modification of the VHL pathway may be transient or partial. Although the precise mechanism for HIF-1α up-regulation is unclear, reports show that oncogenic signaling molecules can attenuate the sensitivity of HIF-1α to VHL under normoxic conditions (57) .
Our data strongly suggest that PI-3K-AKT-mTOR is an upstream participant in IL-1 mediatedNFkB activation and HIF-1α induction. This is supported by the following data: 1) IL-1β induces 473 serine phosphorylation of AKT, which is required for AKT kinase activity (58); 2) IL-1-mediated AKT activation occurs in a PI-3 kinase-dependent manner, and specific inhibition of PI-3 kinase prevents AKT phosphorylation; 3) inhibition of mTOR, a downstream target of AKT (59) abrogates IL-1 mediated NFkB-dependent luciferase expression; and 4) inhibition of AKT or mTOR prevents IL-1 mediated HIF-1α induction. These results are consistent with other reports showing an involvement of the PI-3K-AKT pathway in NFkB activation (16) and with data demonstrating that PI-3 kinase inhibition antagonizes HIF-1α induction by IL-1β (60) . Furthermore, HIF-1α has been reported to be regulated by a mTOR-dependent pathway (61) . Because numerous growth factors that induce HIF-1α via the PI-3K-AKT-mTOR pathway also activate NFkB (62) , future studies should further elucidate the previously unappreciated role of NFkB in HIF-1 activation.
We clearly demonstrate that IL-1 stimulation leads to NFkB activation. Clinically, NFkB plays a major role in various models of carcinogenesis (63), including lung and colon cancers (64, 65) , and therapeutics that antagonize NFkB activity inhibit tumorigenesis (66) . One consequence of NFkB activation is the induction of COX-2 expression and, consistent with these reports, our data demonstrate IL-1 mediated activation of NFkB increases COX-2 protein. In turn, we discovered COX-2 as a potent effector for HIF-1α up-regulation and we validated this observation by showing attenuation of IL-1 mediated HIF-1α up-regulation by COX-2 inhibitors. Moreover, prostaglandin E 2 (PGE 2 ), a major physiological product of COX-2, could also induce HIF-1α protein, further supporting the notion that COX-2 regulates HIF-1 activity at least partially through PGE 2 .
We demonstrate COX-2 mediated HIF-1α induction in both a lung epithelial cell line and a colon cell line. This is clinically significant, as COX-2 plays a major role in pulmonary and intestinal inflammation, a condition correlated with tumor progression in these cancer models (67, 68) . Furthermore, the COX-2 gene product PGE 2 has also been shown to be a major contributor of carcinogenesis (69, 70) . Because COX-2 overexpression promotes angiogenesis and cell survival (71) , at least some of the oncogenic effects of COX-2 may be realized through HIF-1. Our data support this premise, in that IL-1 stimulation results in an up-regulation of HIF-1α protein expression and an associated increase in VEGF expression and secretion. Previous reports also link IL-1 stimulation to VEGF accumulation (41, 72) , although a role for HIF-1 in this pathway has not been well defined.
We now provide evidence that IL-1 mediated VEGF induction is HIF-1 dependent and proceeds via a pathway involving NFkB activation and COX-2 expression. Inhibition of COX-2 prevents IL-1β from increasing VEGF expression, which is in parallel to the effect of these agents upon HIF-1α induction. Furthermore, several reports demonstrate that COX-2 can stimulate expression of VEGF (71) . Interestingly, evidence for the involvement of cyclooxygenase in cancer development first came from pharmacological studies on the cancer-chemopreventive effect of non-steroidal anti-inflammatory drugs (NSAIDs). Collectively, these agents inhibit COX-2 enzymatic activity, resulting in abrogation of prostaglandin biosynthesis. Recently, NSAIDs have been shown to possess anti-tumorigenic properties and to potently down-regulate COX-2 mediated VEGF expression (21, 73) , thereby further emphasizing the tumor-promotion role of COX-2. In addition to its ability to up-regulate VEGF under normoxia, IL-1β also potentiates VEGF induction by hypoxia (74) . Thus, augmentation of HIF-1 activity by both the cytokine and low oxygen tension would be expected to produce an additive or synergistic effect on VEGF (30) . Because a number of solid tumors exist in microenvironments that are both inflammatory and hypoxic (7), it is clinically relevant to investigate whether NFkB/COX-2 is also involved in IL-1 mediated potentiation of VEGF induction under hypoxia.
Our findings suggest that IL-1 mediated HIF-1α up-regulation is a physiological response to inflammatory conditions that can translate an inflammatory signal into an oncogenic signal (Fig.  7) . Recent in vivo studies demonstrating that host-derived IL-1β is critical for tumor growth, angiogenesis, and invasiveness (9, 11) should be revisited in light of the IL-1-HIF-1-VEGF connection. Furthermore, given that NFkB plays a central role in tumor promotion (75), we can now add HIF-1α to the growing list of tumor-promoting signaling molecules in its repertoire.
Our data make a strong case for the previously unappreciated role for HIF-1 in inflammationbased tumor promotion models of cancer. The premise for a tumor-promoting role for HIF-1 in inflammatory, precancerous models is bolstered by the numerous reports documenting HIF-1α up-regulation in response to mediators that are abundant in inflammatory conditions, such as nitric oxide, PGE 2 , and pro-inflammatory cytokines TNF-α and IL-1β (29, 30, 76) . Therefore, this study provides a basic mechanism for an inflammatory etiology of cancer and reveals multiple molecular targets for the development of therapeutic agents. (10 uM) and subsequently treated for 4 h with either IL-1β (500 pg/ml) or hypoxia (1% oxygen), and HIF-1α levels were monitored in nuclear extracts. B) A549 cells were cotransfected with NFkB-dependent luciferase plasmid (0.4 ug) and CMV Renilla luciferase plasmid (4 ng) and subsequently treated with IL-1β (500 pg/ml) for 6 h. One set of cells was transfected with NFκB super repressor plasmid (NFRP, 5 ug), while another was pretreated (30 min) with D609, an NFkB inhibitor. Reporter activities were measured and normalized to CMV Renilla luciferase activity. Data represent the mean of three separate experiments. C) (Upper panel) A549 cells were transfected with NFκB super repressor plasmid for 24 h or pretreated with either SN50 peptide (20 uM) or D609 (50 ug/ml) for 1 h followed by treatment with IL-1β for 4 h, and HIF-1α levels were detected in nuclear extracts. (Lower panel) A549 cells were transfected with NFκB super repressor plasmid or pretreated with D609, followed by treatment with cobalt chloride (100 uM) for 4 h; HIF-1α levels were detected in nuclear extracts. D) A549 cells were treated with IL-1β, and total cellular mRNA was extracted and subjected to RT-PCR, as described in Materials and Methods. β-actin mRNA levels were used as an internal control. The membrane in the upper panel was reprobed with AKT antibody to detect total AKT protein levels. B) A549 cells were cotransfected with NFkB-dependent luciferase plasmid and CMV Renilla luciferase plasmid for 16 h. Cells were then treated with IL-1β (500 pg/ml) for 6 h in the presence or absence of either LY294002(10 uM) or rapamycin (100 nM). Reporter activities were measured and normalized to CMV Renilla luciferase activity. Data represent the mean of three separate experiments. C) A549 cells were treated with IL-1β in the presence or absence of either LY294002 or rapamycin (100 nM), and HIF-1α levels were immunodetected from nuclear extracts. Cycloheximide (CHX, 100 uM) was added to cells either previously untreated or exposed to IL-1β for 4 h. At the times shown, cells were lysed and HIF-1α protein was detected by Western blot. The film was subjected to densitometric analysis by using NIH Image software, and the data were graphically displayed by using Cricket Graph. Lower panel: The blot above was reprobed for ARNT as a loading control. Approximately threefold more protein was loaded for the untreated cells to enable detection of HIF-1α protein. B) Upper panel: Renal carcinoma cells that are deficient for VHL (UMRC2), or a clonally selected line with VHL stably expressed (UMRC2/VHL), were treated with IL-1β (5 ng/ml) for 4 h, and HIF-1α protein was detected in nuclear extracts. Lower panel: A549 cells were transfected with either HA-tagged wild-type HIF-1α or HA-tagged proline mutated (pm) HIF-1α (HIF-1α proline-mutated at residues 402 and 564) to engender resistance to VHL-dependent degradation. Following transfection, cells were treated with IL-1β (500 pg/ml), and HIF-1α in nuclear extracts was immunodetected with an anti-HA antibody. were treated with IL-1β (500 pg/ml) in the presence or absence of the HIF-1 specific inhibitor NSC-609699 (1 µM), and RT-PCR was performed from total RNA as described in Materials and Methods. B) A549 cells were treated as in (A), and immunoreactive VEGF protein in the cell culture supernatants was measured by using the Quantikine VEGF ELISA kit. Data represent the mean of three separate experiments. C) A 549 cells were treated with IL-1β for 8 h in the presence of either NS-398 (25 uM) or indomethacin (25 uM) , and VEGF protein levels were measured as in (B). Data represent the mean of three separate experiments. 
